Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies
This narrative review represents an output from the International Association for the Study of
Pain's global task force on the use of cannabis, cannabinoids, and cannabis-based …
Pain's global task force on the use of cannabis, cannabinoids, and cannabis-based …
THC and CBD: Similarities and differences between siblings
N Stella - Neuron, 2023 - cell.com
Summary Δ 9-tetrahydrocannabinol (THC) and its sibling, cannabidiol (CBD), are produced
by the same Cannabis plant and have similar chemical structures but differ dramatically in …
by the same Cannabis plant and have similar chemical structures but differ dramatically in …
Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial
Cannabidiol (CBD) is increasingly used as analgesic medication although the recent
International Association for the Study of Pain Presidential Task Force on cannabis and …
International Association for the Study of Pain Presidential Task Force on cannabis and …
A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence
Monoacylglycerol lipase (MAGL) regulates endocannabinoid 2-arachidonoylglycerol (2-AG)
and eicosanoid signalling. MAGL inhibition provides therapeutic opportunities but clinical …
and eicosanoid signalling. MAGL inhibition provides therapeutic opportunities but clinical …
International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids …
The President of the International Association for the Study of Pain established a task force
on cannabis and cannabinoid analgesia to systematically examine the evidence on (1) …
on cannabis and cannabinoid analgesia to systematically examine the evidence on (1) …
Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial
S Pramhas, T Thalhammer, S Terner… - The Lancet Regional …, 2023 - thelancet.com
Background Painful knee osteoarthritis (KOA) is common, pharmacological treatment,
however, is often hampered by limited tolerability. Cannabidiol, which preclinically showed …
however, is often hampered by limited tolerability. Cannabidiol, which preclinically showed …
[HTML][HTML] Flawed, futile, and fabricated—features that limit confidence in clinical research in pain and anaesthesia: a narrative review
The randomised controlled trial is the foundation of clinical research; yet there is concern
that many trials have flaws in design, conduct, and reporting that undermine trustworthiness …
that many trials have flaws in design, conduct, and reporting that undermine trustworthiness …
Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy‐induced peripheral neuropathy
DE Sepulveda, DP Morris… - … Journal of Pain, 2022 - Wiley Online Library
Background Cannabigerol (CBG) is a non‐psychoactive phytocannabinoid produced by the
plant Cannabis sativa with affinity to various receptors involved in nociception. As a result …
plant Cannabis sativa with affinity to various receptors involved in nociception. As a result …
Cannabidiol (CBD) in rheumatic diseases (musculoskeletal pain)
KF Boehnke, W Häuser, MA Fitzcharles - Current Rheumatology Reports, 2022 - Springer
Abstract Purpose of Review This review will address the many uncertainties surrounding the
medical use of cannabidiol (CBD). We will begin with an overview of the legal and …
medical use of cannabidiol (CBD). We will begin with an overview of the legal and …
Cannabinoids in chronic pain: therapeutic potential through microglia modulation
NJ van den Hoogen, EK Harding… - Frontiers in Neural …, 2022 - frontiersin.org
Chronic pain is a complex sensory, cognitive, and emotional experience that imposes a
great personal, psychological, and socioeconomic burden on patients. An estimated 1.5 …
great personal, psychological, and socioeconomic burden on patients. An estimated 1.5 …